Who has been buying Genome & Company stock?

2 distinct insiders have filed 0 disclosed insider purchases in Genome & Company (314130), most recently on 2026-05-21. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Genome & Company have?

Genome & Company has 0 buy-side and 2 sell-side disclosures on record, covering ₩155M ($107K) in total reported value, spanning 2024-08-07 to 2026-05-21.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Genome & Company 314130

Company

지놈앤컴퍼니Genome & Company

Insiders

Buys

Total Value

₩155M ($107K)

Avg Return

+0.72%

Last Filing

2026-05-21

Genome & Company (314130) has 0 disclosed insider purchases and 2 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩155M ($107K) in reported transaction value. The earliest filing StockDrifts holds for Genome & Company is dated 2024-08-07; the most recent is 2026-05-21. Across these filings the average return since disclosure is +0.72%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-05-21	SELL	증여	박한수 Park Hansu	Each CEO	-20.0K	₩5,200	-6.7%	₩104M ($72K)
2026-05-21	BUY	수증	차미영 Cha Mi-young	vice president	20.0K	₩5,200	+6.7%	₩104M ($72K)
2026-04-23	BUY	주식매수청구권 행사	서진경 Seo Jin-kyung	Managing Director	26.0K	₩6,100	+15.7%	₩159M ($110K)
2026-03-27	SELL	Market Sell	유현경 Hyeonkyung Yoo	Managing Director	-6.0K	₩9,580	+0.0%	₩57M ($40K)
2026-03-26	SELL	Market Sell	서진경 Seo Jin-kyung	Managing Director	-10.0K	₩9,720	+1.4%	₩97M ($68K)
2025-04-30	SELL	증여	배지수 badge number	Each CEO	-90.0K	₩2,780	-171.9%	₩250M ($174K)
2025-04-30	BUY	수증	박병규 Park Byeong-gyu	Managing Director	50.0K	₩2,780	+171.9%	₩139M ($97K)
2025-04-30	BUY	수증	차미영 Cha Mi-young	Managing Director	20.0K	₩2,780	+171.9%	₩56M ($39K)
2025-04-30	BUY	수증	김상균 Kim Sang-gyun	Managing Director	40.0K	₩2,780	+171.9%	₩111M ($77K)
2025-04-30	BUY	수증	유현경 Hyeonkyung Yoo	Managing Director	20.0K	₩2,780	+171.9%	₩56M ($39K)
2025-04-30	SELL	증여	박한수 Park Hansu	Each CEO	-100.0K	₩2,780	-171.9%	₩278M ($193K)
2025-04-30	BUY	수증	서진경 Seo Jin-kyung	Managing Director	10.0K	₩2,780	+171.9%	₩28M ($19K)
2024-12-06	BUY	기타	차미영 Cha Mi-young	Managing Director	12.0K	₩2,660	+184.2%	₩32M ($22K)
2024-08-07	BUY	무상신주취득	홍유석 Hong Yu-seok	General representative	5.0K	₩5,160	+46.5%	₩26M ($18K)
2024-08-07	BUY	무상신주취득	배지수 badge number	Each CEO	1.6M	₩5,160	+46.5%	₩8.1B ($5.6M)
2024-08-07	BUY	무상신주취득	김상균 Kim Sang-gyun	Managing Director	7.5K	₩5,160	+46.5%	₩39M ($27K)
2024-08-07	BUY	무상신주취득	박한수 Park Hansu	Each CEO	1.7M	₩5,160	+46.5%	₩8.8B ($6.1M)

Frequently asked questions

Who has been buying Genome & Company stock?: 2 distinct insiders have filed 0 disclosed insider purchases in Genome & Company (314130), most recently on 2026-05-21. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Genome & Company have?: Genome & Company has 0 buy-side and 2 sell-side disclosures on record, covering ₩155M ($107K) in total reported value, spanning 2024-08-07 to 2026-05-21.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.